

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417

Status	RECRUITING
Phase	Phase 1
Sponsor	Chugai Pharmaceutical
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (51)

- Signed informed consent form
 - Age ≥ 18 and ≤ 75 at the time of signing informed consent form (except for BP; Age ≥ 18 and ≤ 85 with Karnofsky score $\geq 60\%$ at screening)
 - Ability to comply with the study protocol
 - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods
 - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
- ... and 46 more (see full listing online)

Exclusion (59)

- History of anaphylaxis or hypersensitivity to a biologic agent
 - Active infection requiring systemic antiviral, antibiotics or antifungal
 - Planned surgery during the study
 - Pregnant or breastfeeding, or intending to become pregnant
 - Any serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study
- ... and 54 more (see full listing online)

Locations (69 total)

University of California-Irvine, Orange, California, United States
Johns Hopkins University, Baltimore, Maryland, United States
Northwell Health, LLC PRIME, Lake Success, New York, United States
... and 66 more locations

<https://clinicaltrials.gov/study/NCT06371417>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).